Reviewing Taylor Wimpey (OTCMKTS:TWODY) and Zealand Pharma A/S (OTCMKTS:ZLDPF)

Taylor Wimpey (OTCMKTS:TWODY) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both mid-cap construction companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Volatility & Risk

Taylor Wimpey has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Valuation & Earnings

This table compares Taylor Wimpey and Zealand Pharma A/S’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taylor Wimpey	$4.37 billion	1.47	$433.99 million	N/A	N/A
Zealand Pharma A/S	$49.75 million	115.50	-$102.18 million	($1.82)	-61.29

Taylor Wimpey has higher revenue and earnings than Zealand Pharma A/S.

Analyst Ratings

This is a summary of current ratings and recommmendations for Taylor Wimpey and Zealand Pharma A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taylor Wimpey	0	0	0	0	N/A
Zealand Pharma A/S	0	0	2	0	3.00

Profitability

This table compares Taylor Wimpey and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taylor Wimpey	N/A	N/A	N/A
Zealand Pharma A/S	-213.77%	-36.96%	-30.10%

Summary

Taylor Wimpey beats Zealand Pharma A/S on 6 of the 8 factors compared between the two stocks.

About Taylor Wimpey

Taylor Wimpey plc operates as a homebuilder in the United Kingdom and Spain. It builds and delivers various homes and communities. Taylor Wimpey plc was incorporated in 1935 and is based in High Wycombe, the United Kingdom.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.